Bavarian Nordic (BVNRY) Price & Analysis

Compare

172 Followers

BVNRY Stock Chart & Stats

$12.43

-$0.28(-3.01%)

At close: Jan 08 4:00 PM EST

$12.43

-$0.28(-3.01%)

Day’s Range― - ―

52-Week Range$6.84 - $12.52

Previous CloseN/A

Volume6.49K

Average Volume (3M)910.00

Market Cap

$2.95B

Enterprise Value$1.83B

Total Cash (Recent Filing)$1.66B

Total Debt (Recent Filing)$136.05M

Price to Earnings (P/E)14.1

Beta1.10

Next Earnings

Nov 14, 2025

EPS EstimateN/A

Last Dividend Ex-Date

Mar 27, 2020

Dividend YieldN/A

Share Statistics

EPS (TTM)0.24

Shares Outstanding237,712,550

10 Day Avg. Volume2,379

30 Day Avg. Volume910

Financial Highlights & Ratios

PEG Ratio-0.43

Price to Book (P/B)1.29

Price to Sales (P/S)2.58

P/FCF Ratio56.22

Enterprise Value/Market Cap0.62

Enterprise Value/Revenue0.28

Enterprise Value/Gross Profit0.53

Enterprise Value/Ebitda0.86

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

Bavarian Nordic News

Officials confirm community spread of new Mpox strain in Southern CA, NBC says

The California Department of Public Health and local health agencies have confirmed three unrelated cases of a new...

1d ago

EBS

Bavarian Nordic Reports Strong Earnings and Growth

Bavarian Nordic A/S (($BVNRY)) has held its Q2 earnings call. Read on for the main highlights of the...

2M ago

BVNRY

Bavarian Nordic Reports Strong H1 2025 Results

Bavarian Nordic A/S ( ($BVNRY) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

BVNRY

Bavarian Nordic’s CHIKV VLP Vaccine Study: A Potential Game-Changer in Pediatric Chikungunya Prevention

Bavarian Nordic A/S (($BVNRY)) announced an update on their ongoing clinical study. Study Overview: Bavarian Nordic A/S is...

3M ago

BVNRY

Bavarian Nordic’s Phase 2 Vaccine Trial Update: Key Insights for Investors

Bavarian Nordic A/S (($BVNRY)) announced an update on their ongoing clinical study. The recent update from Bavarian Nordic...

3M ago

BVNRY

Bavarian Nordic Reports Strong Q1 2025 Growth

Bavarian Nordic A/S ( ($BVNRY) ) has released its Q1 earnings. Here is a breakdown of the information...

5M ago

BVNRY

Bavarian Nordic’s Earnings Call: Strong Growth and Positive Outlook

Bavarian Nordic A/S (($BVNRY)) has held its Q1 earnings call. Read on for the main highlights of the...

5M ago

BVNRY

Bavarian Nordic A/S Reports Strong 2024 Earnings Amid Challenges

Bavarian Nordic A/S (($BVNRY)) has held its Q4 earnings call. Read on for the main highlights of the...

8M ago

BVNRY

Bavarian Nordic Reports Strong 2024 Growth

Bavarian Nordic A/S ( ($BVNRY) ) has released its Q4 earnings. Here is a breakdown of the information...

8M ago

BVNRY

Bavarian Nordic Reports Strong Travel Health Growth in 2024

Bavarian Nordic A/S ( ($BVNRY) ) has released its Q3 earnings. Here is a breakdown of the information...

11M ago

BVNRY

Study suggests waning mpox protection from Jynneos vaccine, CIDRAP reports

A preprint article posted on September 11 by medRxiv detailed results of a study that showed that vaccine-generated...

1y ago

EBS

GOVX

Bavarian Nordic announces commercial availability of VAXCHORA in Canada

Bavarian Nordic announced the commercial availability of VAXCHORA, the only single-dose oral vaccine approved in Canada to protect...

1y ago

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

1y ago

EBS

MRVI

Applied Materials, H&R Block report quarterly beats: Morning Buzz

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists....

1y ago

FLO

BVNRY FAQ

What was Bavarian Nordic A/S’s price range in the past 12 months?

Bavarian Nordic A/S lowest stock price was $6.84 and its highest was $12.52 in the past 12 months.

What is Bavarian Nordic A/S’s market cap?

Bavarian Nordic A/S’s market cap is $2.95B.

When is Bavarian Nordic A/S’s upcoming earnings report date?

Bavarian Nordic A/S’s upcoming earnings report date is Nov 14, 2025 which is in 24 days.

How were Bavarian Nordic A/S’s earnings last quarter?

Bavarian Nordic A/S released its earnings results on Aug 22, 2025. The company reported $0.236 earnings per share for the quarter, beating the consensus estimate of N/A by $0.236.

Is Bavarian Nordic A/S overvalued?

According to Wall Street analysts Bavarian Nordic A/S’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bavarian Nordic A/S pay dividends?

Bavarian Nordic A/S pays a Notavailable dividend of $0.426 which represents an annual dividend yield of N/A. See more information on Bavarian Nordic A/S dividends here

What is Bavarian Nordic A/S’s EPS estimate?

Bavarian Nordic A/S’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Bavarian Nordic A/S have?

Bavarian Nordic A/S has 237,712,550 shares outstanding.

What happened to Bavarian Nordic A/S’s price movement after its last earnings report?

Bavarian Nordic A/S reported an EPS of $0.236 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.969%.

Which hedge fund is a major shareholder of Bavarian Nordic A/S?

Currently, no hedge funds are holding shares in BVNRY

Bavarian Nordic Stock Smart Score

Neutral

Blogger Sentiment

Bullish

BVNRY Sentiment 70%
Sector Average ―

Technicals

Fundamentals

Return on Equity

12.17%

Trailing 12-Months

Asset Growth

6.66%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Bavarian Nordic A/S

Bavarian Nordic (BVNRY) is a biotechnology company focused on developing and commercializing innovative vaccines and immunotherapies for infectious diseases and cancer. The company operates primarily in the biotechnology sector, with core products that include its proprietary MVA-BN platform technology, which is utilized in vaccine development for diseases such as smallpox and Ebola, as well as its lead product candidate, the prostate cancer vaccine Prostvac. Bavarian Nordic's commitment to advancing public health through its vaccine portfolio positions it as a key player in the global biopharmaceutical industry.

Bavarian Nordic (BVNRY) Earnings & Revenues

Historic Earnings Reports

BVNRY Company Deck

BVNRY Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call demonstrated strong revenue growth and successful vaccine sales, particularly in the Travel Health and Public Preparedness segments. However, there were some challenges, such as declines in certain vaccine sales and concerns regarding Chikungunya outbreaks. Overall, the positive aspects significantly outweigh the challenges.View all BVNRY earnings summaries